Telix Pharmaceuticals Limited’s (ASX:TLX) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

It is hard to get excited after looking at Telix Pharmaceuticals’ (ASX:TLX) recent performance, when its stock has declined 8.8% over the past three months. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean that the stock could potentially rise in the long-term given how markets usually reward more resilient long-term fundamentals. Specifically, we decided to study Telix Pharmaceuticals’ ROE in this article.

Return on equity or ROE is a key measure used to assess how efficiently a company’s management is utilizing the company’s capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity

So, based on the above formula, the ROE for Telix Pharmaceuticals is:

2.6% = US$11m ÷ US$422m (Based on the trailing twelve months to June 2025).

The ‘return’ is the income the business earned over the last year. Another way to think of that is that for every A$1 worth of equity, the company was able to earn A$0.03 in profit.

See our latest analysis for Telix Pharmaceuticals

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or “retains” for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don’t necessarily bear these characteristics.

As you can see, Telix Pharmaceuticals’ ROE looks pretty weak. Even compared to the average industry ROE of 11%, the company’s ROE is quite dismal. Despite this, surprisingly, Telix Pharmaceuticals saw an exceptional 42% net income growth over the past five years. Therefore, there could be other reasons behind this growth. For instance, the company has a low payout ratio or is being managed efficiently.

As a next step, we compared Telix Pharmaceuticals’ net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 17%.